This educational and interactive workshop, hosted by Huntingdon Life Sciences, will focus on how biotech companies and academia can create value by understanding the drivers for collaboration and investment and using industry expertise to advance asset centric ideas to patients.
Two presenters, Dr Johan Verbeeck, Senior Director, Partnership Management at J&J Innovation, and Dr Christine Robinson, Director Strategic and Corporate Development, Huntingdon Life Sciences, will share their experience about critical success factors that help make a novel drug candidate or target chemistry more appealing for collaboration and investment.
Dr. Johan Verbeeck will present some personal perspectives on creating asset differentiation, advancing novel drug candidates through development stages and understanding the regulatory and clinical landscape. He will also discuss types of partnership or relationship that are potentially available with industry partners.
Dr. Christine Robinson will objectively discuss how utilising industry expertise from CROs and Consultants from different areas such as Preclinical and Clinical Development, CMC, Discovery & Safety Assessment can deliver real innovation and value on a tight budget. This will be supported with practical examples of efficient utilisation of that expertise to create true asset value and innovation.
A light buffet-lunch will be served after the workshop 12pm for further networking.